EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches

Elisabeth Silkenstedt, Martin Dreyling

Hematological Oncology · 2023-06 · 41 (S1) · 36-42

DOI: 10.1002/hon.3149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 09.06.2023. Verfasst von Elisabeth Silkenstedt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, LMU University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. The development and implementation of new targeted and immunotherapeutic approaches have already improved therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk‐adapted, patient‐tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. This review summarizes the current knowledge and standard of care regarding biology and clinical management of MCL, highlighting the implementation of new therapeutic approaches especially targeting the immune system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAdultHumansPrognosisCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsMolecular Biology

Stichwörter der Autor:innen

MCLpathogenesisprognosticationtherapy

Autor:innen und Institutionen

  • Department of Medicine III, LMU University Hospital, Munich, Germany.

Zitieren

APA

Silkenstedt, E., & Dreyling, M. (2023). Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology, 41(S1), 36-42. https://doi.org/10.1002/hon.3149

Vancouver

Silkenstedt E, Dreyling M. Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology. 2023;41(S1):36-42. doi:10.1002/hon.3149

BibTeX
@article{Silkenstedt2023,
  author = {Silkenstedt, Elisabeth and Dreyling, Martin},
  title = {Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches},
  journal = {Hematological Oncology},
  year = {2023},
  volume = {41},
  number = {S1},
  pages = {36--42},
  doi = {10.1002/hon.3149}
}
Kostenlos starten →